Pleural epithelioid angiosarcoma with lymphatic differentiation arisen after radiometabolic therapy for thyroid carcinoma: immunohistochemical findings and review of the literature

Daniela Cabibi 1,4*, Giulia Pipitone 1, Rossana Porcasi 1, Sabrina Ingrao 1, Ignazio Benza 2, Calogero Porrello 3, Massimo Cajozzo 3 and Antonino Giulio Giannone 1

Abstract

Background: Pleural angiosarcoma is a rare tumor that causes diffuse pleural thickening and effusion, mimicking mesothelioma. Immunohistochemistry is needed to highlight endothelial differentiation. We describe the first case of pleural angiosarcoma with lymphatic differentiation following radiometabolic therapy for thyroid carcinoma.

Case presentation: A 50-year-old man showed diffuse pleural thickening and effusion. Nine years earlier, he underwent thyroidectomy and radiometabolic therapy for thyroid carcinoma with lymph node metastases. Histologically, the tumor consisted of a solid proliferation of atypical epithelioid cells and anastomosed vascular spaces, lacking of red blood cells and containing Alcian blue positive material. The tumor showed positive immunostaining for Vimentin, CD31, CK7, D2–40, c-MYC, Ki67, focal positivity for PanCK, and negative immunostaining for Factor VIII, CD34, WT1, Calretinin, EMA, HBME-1, CEA, p63, EpCAM, Bcl-2, TTF1 and Thyroglobulin. CD99 showed a granular/paranuclear pattern of positivity. The histological and immunohistochemical features were consistent with “pleural angiosarcoma with lymphatic differentiation, epithelioid variant”.

Discussion and conclusions: Epithelioid angiosarcoma with lymphatic differentiation is very rare and aggressive. Moreover, the positivity for c-MYC suggests the relationship with radiometabolic therapy. To our knowledge, this is the first case of pleural c-MYC-positive angiosarcoma with lymphatic differentiation reported in the literature and the first one arisen after radiometabolic therapy for thyroid carcinoma.

Keywords: Pleural angiosarcoma, Radiometabolic therapy, Immunohistochemistry, Thyroid Carcinoma

Background

Angiosarcoma (AS) is a malignant neoplasm with endothelial differentiation, accounting for approximately 1–2% of all soft tissue sarcomas. Pleura represents an exceedingly rare site for AS, with about 50 cases reported in the literature [1]. Patients almost always die from the disease within months. The diagnosis of this rare pleural tumor is challenging, mimicking mesothelioma, pulmonary carcinoma, or metastatic adenocarcinoma, due to non-specific clinical and radiologic findings and to the positivity for epithelial markers, such as pan-cytokeratins (PanCK) and CK7. Markers of endothelial differentiation, such as CD31, CD34 and Factor VIII, are particularly useful in the identification of these tumors [2, 3].

Lymphangiosarcoma (LAS) is even rare. Both AS and LAS typically arise about 10 years after axillary nodal dissection or radiation therapy for breast cancer with long-standing massive lymphedema [4] and have been
reported in literature as Stewart-Treves Syndrome. LAS has been also evidenced after chronic lymphedema of lower leg [5]. In serous membranes, few cases of LAS have been reported after therapeutic irradiation [6].

We describe a case of primary pleural epithelioid AS with lymphatic differentiation, clinically and radiologically suspected as mesothelioma, arisen 9 years after radiometabolic therapy (RMT) for thyroid papillary carcinoma with multiple lymph node metastases. To the best of our knowledge, only one case of pleural epithelioid LAS has been previously reported [1]. It is noteworthy that this is the first reported case of pleural epithelioid AS with lymphangioendothelial differentiation arisen after RMT for thyroid carcinoma.

Case report
A 50 year-old male patient with a history of dyspnea was admitted to our hospital.

Past medical history
Nine years earlier, in another hospital, the patient underwent total thyroidectomy for papillary carcinoma with dissection of the back-left jugular lymph nodes, one of which metastatic.

The tumor was located in the upper half of the left lobe and had a maximum diameter of 4,5 cm. The histologic examination revealed a well differentiated papillary carcinoma, classical variant, with multiple microscopic foci in both lobes of the thyroid gland; the tumor stained positively for TTF1 and Thyroglobulin. One out of 8 foci in both lobes of the thyroid gland; the tumor stained for CEA and negative for TTF1 and Thyroglobulin. One out of 8 lymph nodes was metastatic.

After six months, PET and total body scintigraphy evidenced the presence of lymph node metastases on the left side of the neck (level III and IV), and the patient underwent RMT with iodine-131 (131I, 100 mCi).

Subsequently, he was subjected to surgical lymphadenectomy of 22 cervical and supraclavicular lymph nodes, three of which metastatic. Due to the persistence of residual lymph node metastases, he underwent three cycles of RMT (100 mCi; 3,7GBq orally). So, he received a cumulative dose of 400 mCi. It is noteworthy that before the third cycle of RMT, the total body scintigraphy evidenced low and widespread 131I uptake in both lungs and in the para-medial left mediastinal area, leading to the suspicion of mediastinal and lung involvement. Thoracic PET and CT did not evidence nodular lesions, ruling out the suspicion of metastasis.

Finally, a new lymphadenectomy was performed, due to the persistence of metastases in 2/4 retro-claverear lymph nodes, in 4/22 level II left lymph nodes and in level III left lymph nodes.

Current medical history
The chest x-ray showed an opaque left hemithorax, saving a small central lung area with contralateral cardio-mediastinal shift [Fig. 1]. CT images showed irregular circumferential pleural thickening with nodular soft tissue masses involving the mediastinal and diaphragmatic pleura, extending into the fissures and reducing the volume of the right lung. These features clinically suggested pleural mesothelioma, and multiple biopsies of the left parietal pleura were performed during Video-Assisted Thoracotomy (VATS).

On microscopic examination, the hematoxylin-eosin (H-E) sections of formalin-fixed paraffin-embedded biopsies showed a neoplastic proliferation of highly atypical epithelioid cells with mitoses and areas of necrosis. The tumor was composed of solid areas [Fig. 2a, b] and “vasoformative” areas with variably sized anastomotic vascular spaces, lined by atypical endothelial cells with plump and prominent nuclei. Most of the vascular spaces were lacking of red blood cells and contained certain amounts of Alcian blue positive material [Fig. 2c, d]. The immunohistochemical analysis showed positive immunostaining for Vimentin, CK7, D2–40 and focally for PanCK [Fig. 3a-d], both in the vascular and in the solid areas. The vascular endothelial lining showed focal positivity for CD31 [Fig. 4a,d]. CD34, Factor VIII related-antigen and WT1 stained positively only in a few non-neoplastic vascular channels that were used as positive internal control [Fig. 4b-d]. CD99 showed a paranuclear pattern and/or granular pattern of positivity [Fig. 4c]. Nuclei of many tumor cells stained positively for c-MYC [Fig. 4f]. Calretinin, CK5/6, EMA, HBME-1, TTF-1, Thyroglobulin and CEA stained negatively [Fig. 5a-g]. The expression of Ki67 was high, with about 30% of positive neoplastic nuclei [Fig. 5h]. Finally, negative immunostaining was evidenced for p63, Bcl-2, EpCAM and LNA-1 HHV8. The overall morphologic and immunohistochemical features supported the diagnosis of pleural malignant epithelioid vascular tumor, consistent with epithelioid AS with lymphatic differentiation.

Discussion
Pleural AS is a rare malignant neoplasm composed of atypical and pleomorphic endothelial cells lining abnormal vascular spaces. The radiologic features are nonspecific and usually show unilateral or bilateral effusion and diffuse pleural thickening that can easily simulate mesothelioma or metastases. Mass lesions are seen in about half of the patients [2, 3]. There are two histological variants of pulmonary/pleural AS: classical and epithelioid. Classical AS exhibits a “vasoformative” pattern, with irregular anastomotic vascular spaces containing red blood cells, lined by atypical endothelial cells. “Vasoformative” component is focal in epithelioid AS, that instead shows a
predominant solid growth pattern composed of large, round to polygonal epithelioid cells with abundant eosino-philic cytoplasm, large pleomorphic nuclei and prominent nucleoli. Epithelioid features are mentioned in the majority of pleural AS (72.5%) and constitute a variable proportion of the tumors [2, 7].

Immunohistochemical staining play an important role in the differential diagnosis. Our case consisted of both solid epithelioid areas and anastomosing vascular areas. It showed co-expression of Vimentin, CK7, D2–40, focal PanCK, but it stained negatively for EMA, CEA, EpCAM, usually positive in sarcomatoid carcinoma. The negative

![Fig. 1 CT image revealed irregular circumferential pleural thickening with nodular soft tissue masses, involving the mediastinal and diaphragmatic pleura, and extending into the fissures, with reduction of right lung volume.](image1.png)

![Fig. 2 a On low power magnification, the tumor consisted of “vasoformative” areas admixed with more solid areas. b Solid areas constituted by highly atypical epithelioid cells. c “Vasoformative” areas characterized by vascular channels lined by plumped atypical cells, lacking of red blood cells. d Vascular channels containing Alcianblue positive mucoid substance. a. 40x, H-E; b. 200x, H-E; c. 100x, H-E; d. Alcian-PAS, 200x](image2.png)
immunostaining for EMA and for markers usually positive in mesothelioma, such as CK5/6, Calretinin, HBME1, together with the positive immunostaining for CD31, were useful in the differential diagnosis with mesothelioma. CD31 in fact is a marker of vascular lineage, more sensible and specific than CD34, WT1, FVIII, and it is almost always negative in non-vascular neoplasms, such as mesotheliomas and carcinomas [3, 8, 9].

Among the vascular neoplasias, the differential diagnosis between angiosarcoma and epithelioid hemangiendothelioma can be very challenging. Epithelioid hemangiendothelioma typically arises from blood vessels with a characteristic appearance at low-power magnification and it is composed of short strands or solid nests of epithelioid endothelial cells. Distinct vascular spaces are rarely observed and more frequently the tumor cells form small...
intracellular lumens. Conversely, epithelioid angiosarcomas are composed of solid sheets of highly atypical, mitotically active epithelioid cells of endothelial lineage. Necrosis is common, and vascular differentiation is evidenced by the formation of irregular sinusoidal vascular channels in the “vasoformative” areas [10].

Some authors reported that grade 3 AS could co-express both blood and lymphatic markers [11]. On the other side, Kahn et al. stated that D2–40 stains all benign lymphatic tumors but not benign proliferations of blood vessel origin. So, they concluded that “a subset of AS with positive D2-40 cells can bear partial differentiation along the lymphatic endothelial lineage and should be classified as LAS” [12].

In our case, the presence of sinusoidal vascular channels lacking of red blood cells and containing amorphous Alcian blue positive substance, the marked cellular atypia, the presence of necrosis and numerous atypical mitoses, the high Ki67 expression and the positive immunostaining for CD31 and D2–40 were more consistent with the diagnosis of “epithelioid angiosarcoma with lymphatic differentiation”.

Finally, for both the morphological and immunohistochemical features it is worth noting the negative immunostaining for TTF1 and thyroglobulin. This makes unlikely to assume metastasis from the well differentiated papillary carcinoma, that stained positively for TTF1 and thyroglobulin and surgically removed nine years earlier. Although the expression of CD99 has been reported in several malignant neoplasias and it is not specific, the focal expression of CD99 was in keeping with previous studies highlighting CD99 staining in 25% of the epithelioid sarcomas [13].

AS represents a well-known complication in the setting of chronic lymphedema (Stewart-Treves Syndrome) and after radiotherapy for breast carcinoma, carcinoma of the vulva and Hodgkin lymphoma [14–16]. Primary pleural AS is very rare and the pathogenesis is still unknown. Recently, Zhang et al. described a case of “de novo pleural epithelioid AS” and they found only 18 cases of primary AS of the pleura previously reported in the literature [17].

Some case reports from Japan indicate the relationship with chronic tuberculous pyothorax [18, 19]. A history of exposure to radiation or asbestos was noted in a few Western cases [3]. Our patient was repeatedly subjected to lymphadenectomy but he never showed signs of lymphatic stasis. It is noteworthy that during the treatment, a total-body scintigraphy evidenced a low and widespread uptake of $^{131}$I in both lungs and in the para-medial left mediastinal area.

Moreover, the positivity for c-MYC is in keeping with recent studies reporting that positive nuclear immunostaining for c-MYC “can reliably discriminate between...
AS secondary to irradiation and AS arising de novo, that are morphologically indistinguishable” [20–23].

Previous studies suggested that the exposure to ionizing radiation from radioisotope therapy or external local radiotherapy raises the risk of developing second primary cancers, and the risk increases with cumulative doses of 131I [24–29]. Our patient received a 131I cumulative dose of 400 mCi and he died four months after the diagnosis.

Conclusions
In this case of c-MYC positive pleural angiosarcoma with lymphatic differentiation, a pathogenetic relationship between the pleural AS and the oncogenic effects of the ionizing radiations could be hypothesized. To the best of our knowledge, this is the first case of pleural AS with lymphatic differentiation following radiometabolic exposure for metastatic thyroid papillary carcinoma and the first pleural AS with lymphatic differentiation in which c-MYC positivity has been highlighted.

Abbreviations
AS: Angiosarcoma; CEA: Carcino-embrionic antigen; CK: Cytokeratin; EMA: Epithelial membrane antigen; H&ME-1: Hector Battifora Mesothelial-1; H&E: Hematoxylin and eosin; LAS: Lymphangiosarcoma; RMT: Radiometabolic therapy; TTF1: Thyroid transcription factor; VATS: Video-Assisted Thoracotomy; WT1: Wilms Tumor-1

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
All data generated or analyzed during this study are included in the below published article.

Authors’ contributions
CD conceived and designed the study, contributed to the interpretation of the data, and drafted the article, revising it critically for important intellectual content. PG, PR, IS, BI, PC and CM contributed to the acquisition of data and drafted the manuscript. GAG contributed to the analysis and interpretation of the data, and drafted the article, revising it critically for important intellectual content. All authors read and approved the final version of the manuscript to be published.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this Journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Sciences for the Promotion of Health and Mother and Child Care, Anatomic Pathology, University of Palermo, Palermo, Italy. 2Bucchieri La Ferla Hospital, Unit of Radiology, Palermo, Italy. 3Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy. 4Anatomia Patologica, A.O.U. Pollicino P. Giaccone, Via del Vespri 129, 90127 Palermo, Italy.

Received: 13 May 2017 Accepted: 8 August 2017
Published online: 15 August 2017

References
1. Quesada A, Quesada J, Khalil K, et al. Morphoproteomic study of primary pleural angiosarcoma of lymphangiendothelial lineage: a case report. Ann Clin Lab Sci. 2013;43(3):317–22.
2. Kao YC, Chow JM, Wang KM, et al. Primary pleural angiosarcoma as a mimicker of mesothelioma: a case report. **V*V* Diagn Pathol. 2011;6:130.
3. Zhang P, Livolsi VA, Brooks JJ. Malignant epithelioid vascular tumors of the pleura: report of a series and literature review. Hum Pathol. 2000;31(1):29–34.
4. Sepah YJ, Umer M, Qureshi A, et al. Lymphangiosarcoma of the arm presenting with lymphedema in a woman 16 years after mastectomy: a case report. Cases J. 2009;2:66897.
5. Centi A, Gianni C, Corbellino M, et al. Lymphangiosarcoma of the pubic region: a rare complication arising in congenital non-hereditary lymphedema. Eur J Dermatol. 1998;8(1):511–4.
6. McCaughey WT, Dardick I, Barr JR. Angiosarcoma of serous membranes. Arch Pathol Lab Med. 1983;107(6):304–7.
7. Maglara GC, Katsenos S, Kakadellis J, et al. Primary angiosarcoma of the lung and pleura. Monaldi Arch Chest Dis. 2003(64)(1):234–6.
8. De Young BR, Frierson HF Jr, Ly MN, Smith D, Swanson PE. CD31 immunoreactivity in carcinomas and mesotheliomas. Am J Clin Pathol. 1998;110(3):374–7.
9. Danese E, Pozzi B, Milani M, et al. Primary pleural epithelioid angiosarcoma. A case report and review of the literature. Pathol Res Pract. 2010;206(6):415–9.
10. Goldblum JR, Folpe AL, Weiss SW, editors. Enzinger & Weiss’ Soft tissue tumors, 6th ed. Philadelphia: Elsevier (Saunders); 2014.
11. Verdié E, Carvalho E, Young P, et al. Lymphangiosarcoma treated with liposomal doxorubicin (Caelyx). Ann Dermatol Venereol. 2007;134(10pt1):760–3.
12. Kahn HU, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15(4):434–40.
13. Hasegawa T, Matsuno Y, Shimoda T, et al. Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases. Mod Pathol. 2001;14(7):655–63.
14. Leborgne F, Falconi LM. Lymphangiosarcoma of the anterior abdominal wall: a case report. Cancer. 1980;46(3):1228–30.
15. Huey GR, Stehman FB, Roth LM, et al. Lymphangiosarcoma of the edematous thigh after radiation therapy for carcinoma of the vulva. Gynecol Oncol. 1985;20(3):394–401.
16. Azurdia RM, Gueirin DM, Verbov JL. Chronic lymphoedema and angiosarcoma. Clin Exp Dermatol. 1999;24(4):270–2.
17. Zhang S, Zheng Y, Liu W, Yu X. Primary epithelioid angiosarcoma of the pleura: a case report and review of literature. Int J Clin Exp Pathol. 2015;8(2):2153–8.
18. Klima M, Ito H, Furuta T, et al. Pyothorax-associated angiosarcoma of the pleura with metastasis to the brain. Pathol Int. 2003;53(8):547–51.
19. Aozasa K, Naka N, Tomita Y, et al. Angiosarcoma developing from chronic pyothorax. Mod Pathol. 1994;7(9):906–11.
20. Guo T, Zhang L, Chang NE, et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer. 2011;50(1):25–33.
21. Mentzel T, Schidhaus HU, Palmedo G. Postirradiation cutaneous angiosarcoma aftertreatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases; clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol. 2012;25(1):75–85.
22. Leal M, Lebel A, Hamel-Viard F, et al. Can c-myc amplification reliably discriminate postirradiation from primary angiosarcoma of the breast? Cancer Radiother. 2015;19(3):168–74.
23. Comerjo KM, Deng A, Wu H, Cosar EF, et al. The utility of MYC and FLT4 in the diagnosis and treatment of postirradiation atypical vascular lesion and angiosarcoma of the breast. Hum Pathol. 2015;46(6):868–75.
24. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89(9):1638–44.
25. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to 3 decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93(2):504–15.
26. Kim C, Bi X, Pan D, et al. The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid. 2013;23(5):575–82.
27. Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery. 2012;151(6):844–50.
28. Iyer NG, Moris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117(19):4439–46.
29. Cho YY, Lim J, Oh CM, Byu J, Jung KW, Chung JH, Won YJ, Kim SW. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea. Cancer. 2015;121(2):259–68.